AstraZeneca’s Enhertu Gets FDA Approved as First Therapy for HER2-Low Breast Cancer
XTalks
AUGUST 10, 2022
HER2-low is characterized by the presence of some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. In the US, it is estimated that 287,850 new cases of female breast cancer will be diagnosed in 2022, according to data from the National Cancer Institute (NCI) outlined by the FDA. percent of the group.
Let's personalize your content